Chemotherapy‐induced peripheral neuropathy: a current review
Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
Chemotherapy-induced peripheral neuropathy: A current review.
NP Staff, A Grisold, W Grisold, AJ Windebank - Annals of Neurology, 2017 - europepmc.org
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30–40% of patients …
experienced by patients receiving treatment for cancer. Approximately 30–40% of patients …
[HTML][HTML] Chemotherapy-Induced Peripheral Neuropathy: A Current Review
NP Staff, A Grisold, W Grisold… - Annals of neurology, 2017 - ncbi.nlm.nih.gov
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30–40% of patients …
experienced by patients receiving treatment for cancer. Approximately 30–40% of patients …
Chemotherapy-induced peripheral neuropathy: A current review
NP Staff, A Grisold, W Grisold… - Annals of …, 2017 - pubmed.ncbi.nlm.nih.gov
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
Chemotherapy‐induced peripheral neuropathy: A current review
NP Staff, A Grisold, W Grisold, AJ Windebank - Annals of Neurology, 2017 - infona.pl
Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
Chemotherapy-induced peripheral neuropathy: A current review
NP Staff, A Grisold, W Grisold… - Annals of …, 2017 - mayoclinic.elsevierpure.com
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
Chemotherapy‐induced peripheral neuropathy: A current review
NP Staff, A Grisold, W Grisold, AJ Windebank - Annals of Neurology, 2017 - cir.nii.ac.jp
抄録< jats: p> Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐
limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 …
limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 …
Chemotherapy-induced peripheral neuropathy: A current review.
NP Staff, A Grisold, W Grisold, AJ Windebank - Annals of Neurology, 2017 - europepmc.org
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30–40% of patients …
experienced by patients receiving treatment for cancer. Approximately 30–40% of patients …